# Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

> **NCT03958565** · — · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 100 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** Tyrosine Kinase Inhibitor
- **DRUG:** Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
- **DRUG:** Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]

## Key facts

- **NCT ID:** NCT03958565
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-28
- **Primary completion:** 2028-03-05
- **Final completion:** 2028-04-28
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958565, "Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03958565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*